Indication for stereotactic radiotherapy of the macula with IRay® for wet age-related macular degeneration

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00009593

Enrollment

800

Registered

2015-11-02

Start date

2015-12-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H35.3

Interventions

Group 1: all patients with wet AMD (age-related macular degeneration) treated within a time frame of 4 months in the hospital are checked for inclusion/exclusion criteria for an IRay treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: wet age related macular degeneration, previously treated with intravitreal injections

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Proportion of patients who are eligible for IRay treatment	—

Secondary

Measure	Time frame
characteristics of patient eligible for IRay: clinical history (number of treatments within last 6/12 months, number of different drugs, visual acuity before treatment and at time of analysis); description of clinical evaluation (SRT offered/planned/performed/delayed); analysis of patient response to IRay treatment (declined? reasons); description of patients not eligible: reasons (characteristics of AMD, ocular comorbidity, systemic comobidity), was IRay possible at a time before this evaluation? description of clinical course of patients who were eligible before (number of intravitreal injections)	—

Measure

Time frame

characteristics of patient eligible for IRay: clinical history (number of treatments within last 6/12 months, number of different drugs, visual acuity before treatment and at time of analysis); description of clinical evaluation (SRT offered/planned/performed/delayed); analysis of patient response to IRay treatment (declined? reasons); description of patients not eligible: reasons (characteristics of AMD, ocular comorbidity, systemic comobidity), was IRay possible at a time before this evaluation? description of clinical course of patients who were eligible before (number of intravitreal injections)

—

Countries

Germany

Contacts

Public ContactChristoph Ehlken

Universitäts-Augenklinik Freiburg

christoph.ehlken@uniklinik-freiburg.de076127040523

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026